186 related articles for article (PubMed ID: 34972751)
21. TRPS1 is a promising marker for all subtypes of breast cancer.
Lui JW; Tsang JY; Li J; Ko CW; Tam F; Loong TC; Tse GM
Histopathology; 2024 Apr; 84(5):822-836. PubMed ID: 38173281
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
[TBL] [Abstract][Full Text] [Related]
23. A pilot study: Comparison of TRPS1 and GATA3 immunoperoxidase staining using cytologic smears in entities reportedly positive for GATA3.
Rohra P; Ding C; Yoon EC; Gan Q
Cancer Cytopathol; 2022 Dec; 130(12):930-938. PubMed ID: 35790088
[TBL] [Abstract][Full Text] [Related]
24. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin.
Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G
Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444
[TBL] [Abstract][Full Text] [Related]
25. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
26. SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells.
Feng W; Liu S; Zhu R; Li B; Zhu Z; Yang J; Song C
Biochem Biophys Res Commun; 2017 Apr; 485(2):522-528. PubMed ID: 28189679
[TBL] [Abstract][Full Text] [Related]
27. Trichorhinophalangeal Syndrome Type 1 Is a Highly Sensitive and Specific Marker for Diagnosing Triple-Negative Breast Carcinomas on Cytologic Samples.
Lynn TJ; Shi J; Liu H; Monaco SE; Prichard JW; Lin F
Arch Pathol Lab Med; 2024 Jan; 148(1):e1-e8. PubMed ID: 37406296
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
Kim SW; Kim HS; Na K
Anticancer Res; 2020 Oct; 40(10):5925-5932. PubMed ID: 32988924
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of GATA3 Versus BRST2 for the Identification of Metastatic Breast Carcinoma in the Upper GI Tract: Which Performs Better?
Salagean D; Streutker C; Faragalla H; Jakate K
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):501-507. PubMed ID: 29629946
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma.
Jin L; Qin C; Qi X; Hong T; Yang X; Zhu X
Transl Cancer Res; 2020 Sep; 9(9):5603-5613. PubMed ID: 35117924
[TBL] [Abstract][Full Text] [Related]
31. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
[TBL] [Abstract][Full Text] [Related]
32. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
[TBL] [Abstract][Full Text] [Related]
33. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
[TBL] [Abstract][Full Text] [Related]
34. ZNF503 combined with GATA3 is a prognostic factor in triple-negative breast cancer.
Liu S; Cao X; Li J; Liu J
Biomarkers; 2023 Dec; 28(5):437-447. PubMed ID: 37036735
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer.
Han R; Nofech-Mozes S; Boles D; Wu H; Curcin N; Slodkowska E
Int J Surg Pathol; 2024 Apr; 32(2):239-251. PubMed ID: 37306115
[No Abstract] [Full Text] [Related]
36. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
[TBL] [Abstract][Full Text] [Related]
37. SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.
Adkins BD; Geromes A; Zhang LY; Chernock R; Kimmelshue K; Lewis J; Ely K
Head Neck Pathol; 2020 Jun; 14(2):406-411. PubMed ID: 31222589
[TBL] [Abstract][Full Text] [Related]
38. GATA3 expression in triple-negative breast cancers.
Byrne DJ; Deb S; Takano EA; Fox SB
Histopathology; 2017 Jul; 71(1):63-71. PubMed ID: 28211079
[TBL] [Abstract][Full Text] [Related]
39. Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma.
Stolnicu S; Tunde C; Cadar A; Boros M
Pol J Pathol; 2020; 71(1):62-65. PubMed ID: 32429656
[TBL] [Abstract][Full Text] [Related]
40. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
Chiesa-Vottero A
Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
